Preparing your results

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy.

To investigate mechanisms in the pathogenesis of cardiomyopathy associated with mutations of the dystrophin-glycoprotein complex, we analyzed genetically engineered mice deficient for either alpha-sarcoglycan (Sgca) or delta-sarcoglycan (Sgcd). We found that only Sgcd null mice developed cardiomyopathy with focal areas of necrosis as the histological hallmark in cardiac and skeletal muscle. Absence of the sarcoglycan-sarcospan (SG-SSPN) complex in skeletal and cardiac membranes was observed in both animal models. Loss of vascular smooth muscle SG-SSPN complex was only detected in Sgcd null mice and associated with irregularities of the coronary vasculature. Administration of a vascular smooth muscle relaxant prevented onset of myocardial necrosis. Our data indicate that disruption of the SG-SSPN complex in vascular smooth muscle perturbs vascular function, which initiates cardiomyopathy and exacerbates muscular dystrophy.

Pubmed ID: 10481911


  • Coral-Vazquez R
  • Cohn RD
  • Moore SA
  • Hill JA
  • Weiss RM
  • Davisson RL
  • Straub V
  • Barresi R
  • Bansal D
  • Hrstka RF
  • Williamson R
  • Campbell KP



Publication Data

August 20, 1999

Associated Grants

  • Agency: NIDDK NIH HHS, Id: DK25295

Mesh Terms

  • Animals
  • Cardiomyopathy, Dilated
  • Carrier Proteins
  • Coronary Vessels
  • Cytoskeletal Proteins
  • Macromolecular Substances
  • Membrane Glycoproteins
  • Membrane Proteins
  • Mice
  • Mice, Knockout
  • Muscle, Smooth, Vascular
  • Muscular Dystrophy, Animal
  • Myocardium
  • Necrosis
  • Neoplasm Proteins
  • Physical Conditioning, Animal
  • Sarcoglycans